MedPath
EMA Product

Xerava

Product approved by European Medicines Agency (EU)

Basic Information

Xerava

Regulatory Information

EMEA/H/C/004237

Authorised

September 20, 2018

9

November 6, 2024

Company Information

Germany

Heussstraße 25 Brand 52078 Aachen

Paion Pharma GmbH

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Overview Summary

Xerava is an antibiotic used to treat complicated intra-abdominal (belly) infections (cIAI) in adults. ‘Complicated’ means that the infection is difficult to treat because it has spread to the abdominal space. Xerava contains the active substance eravacycline.

© Copyright 2025. All Rights Reserved by MedPath